In this study we investigated the experience of Mangiferin in patient with metabolic syndrome (MS). A total of 20 patients were selected and divided into two groups (the mean age was 50,34±0,9 years), i.e. MS before treatment (BT) and MS with mangiferin treatment at 250 mg orally twice a day for 4 weeks (AT). We analyzed data of lipid profile, coagulogram, liptin, insulin, C-peptid, HbA1c and levels of total immunoglobulins A (IgA), G (Ig G), M (Ig M) in plasma. Mean levels of total cholesterol and low density lipoproteins were significantly higher in patients with MS and BT as compared to MS and AT group (6,20±0,20mmol/l vs 5,70±0,20mmol/l; р<0,05, 3,94±0,20mmol/l vs 3,52±0,20mmol/l; р<0,05 respectively). Mean values of C-peptid was also higher in subjects with MS and BT than in subjects with MS and AT (1221,27±128,40 vs 812,04±122,60 pmol/l; р<0,05). Mean levels of total IgA was significantly higher in patient with MS and AT as compared to MS and BT group (2,52±0,60g/l vs 1,30±0,50g/l (р<0,05). The treatment with Mangiferin was associated with hypolipidemic, immunomodulatoty effects and decline of insulin resistance level in patients with MS.
|Translated title of the contribution||The experience of Mangiferin in metabolic syndrome|
|Journal||Справочник врача общей практики|
|State||Published - 5 Apr 2019|
- MENOPAUSAL METABOLIC SYNDROME